Bg pattern

IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Imipenem/Cilastatin Aurovitas 500 mg/500 mgpowder for solution for infusion EFG

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Imipenem/Cilastatin Aurovitas and what is it used for
  2. What you need to know before you use Imipenem/Cilastatin Aurovitas
  3. How to use Imipenem/Cilastatin Aurovitas
  4. Possible side effects
  5. Storage of Imipenem/Cilastatin Aurovitas
  6. Contents of the pack and other information

1. What is Imipenem/Cilastatin Aurovitas and what is it used for

Imipenem/cilastatin belongs to a group of medicines called carbapenem antibiotics. It eliminates a wide variety of bacteria (germs) that cause infections in different parts of the body in adults and children over one year of age.

Antibiotics are used to treat bacterial infections and are not effective against viral infections such as the flu or the common cold.

It is essential that you follow the instructions regarding dosage, administration, and duration of treatment indicated by your doctor.

Do not store or reuse this medication. If you have any leftover antibiotic after completing treatment, return it to the pharmacy for proper disposal. Do not throw medicines down the drain or into the trash.

Treatment

Your doctor has prescribed imipenem/cilastatin because you have one (or more) of the following types of infections:

  • Complicated infections in the abdomen
  • Infection affecting the lungs (pneumonia)
  • Infections that can be acquired during or after childbirth
  • Complicated urinary tract infections
  • Complicated skin and soft tissue infections

Imipenem/cilastatin can be used to treat patients with low white blood cell counts who have fever and are suspected of having a bacterial infection.

Imipenem/cilastatin can be used to treat blood infections caused by bacteria, which may be associated with one of the aforementioned types of infections.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Imipenem/Cilastatin Aurovitas

Do not use Imipenem/Cilastatin Aurovitas

  • If you are allergic to imipenem, cilastatin, or any of the other components of this medicine (listed in section 6).
  • If you are allergic to other antibiotics such as penicillins, cephalosporins, or carbapenems.

Warnings and precautions

Tell your doctor about any problems you have or have had, such as:

  • Allergies to any medication, including antibiotics (unexpected allergic reactions that can be life-threatening require immediate medical treatment)
  • Colitis or any other gastrointestinal disease
  • Any disorder of the central nervous system, such as localized tremors or epileptic seizures
  • Liver, kidney, or urine problems

You may develop a positive test (Coombs test), which indicates the presence of antibodies that can destroy red blood cells. Your doctor will discuss this with you.

Tell your doctor if you are taking valproic acid or sodium valproate (see Using Imipenem/Cilastatin Aurovitas with other medicinesbelow).

Children

Imipenem/cilastatin is not recommended for administration in children under one year of age or children with kidney problems.

Using Imipenem/Cilastatin Aurovitas with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

Tell your doctor if you are taking ganciclovir, which is used to treat some viral infections.

Also, tell your doctor if you are taking valproic acid or sodium valproate (used to treat epilepsy, bipolar disorder, migraine, or schizophrenia) or any anticoagulant medication such as warfarin.

Your doctor will decide if you should use imipenem/cilastatin in combination with these medicines.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Imipenem/cilastatin has not been studied in pregnant women. Imipenem/cilastatin should not be used during pregnancy unless your doctor decides that the potential benefit justifies the potential risk to the fetus.

Small amounts of this medicine may pass into breast milk and may affect the baby. Therefore, your doctor will decide if you should use imipenem/cilastatin during breastfeeding.

Consult your doctor or pharmacist before using any medicine.

Driving and using machines

There are some side effects associated with this product (such as seeing, hearing, or feeling something that is not there, dizziness, drowsiness, and a sensation of objects spinning) that can affect some patients' ability to drive or operate machinery (see section 4).

Imipenem/Cilastatin Aurovitas contains sodium

Patients on low-sodium diets should note that this medicine contains 37.6 mg (1.6 mmol) of sodium per dose.

3. How to use Imipenem/Cilastatin Aurovitas

Imipenem/cilastatin will be prepared and administered by a doctor or other healthcare professional. Your doctor will decide how much imipenem/cilastatin you need.

Use in adults and adolescents

The usual dose of imipenem/cilastatin for adults and adolescents is 500 mg/500 mg every 6 hours or 1,000 mg/1,000 mg every 6 or 8 hours. If you have kidney problems, your doctor may reduce your dose.

Use in children

The usual dose in children over one year of age is 15/15 or 25/25 mg/kg/dose every 6 hours. Imipenem/cilastatin is not recommended in children under one year of age and in children with kidney problems.

Method of administration

Imipenem/cilastatin is administered intravenously (into a vein) over 20-30 minutes for a dose of ≤500 mg/500 mg or 40-60 minutes for a dose of >500 mg/500 mg.

If you use more Imipenem/Cilastatin Aurovitas than you should

Overdose symptoms may include seizures, confusion, tremors, nausea, vomiting, low blood pressure, and slow heart rate. If you are concerned that you may have received too much imipenem/cilastatin, contact your doctor or other healthcare professional immediately.

If you forget to use Imipenem/Cilastatin Aurovitas

If you are concerned that you may have missed a dose, contact your doctor or other healthcare professional immediately.

Do not take a double dose to make up for missed doses.

If you stop using Imipenem/Cilastatin Aurovitas

Do not stop using imipenem/cilastatin until your doctor tells you to.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Common(may affect up to 1 in 10 people):

  • Nausea, vomiting, diarrhea. Nausea and vomiting seem to occur more frequently in patients with a low white blood cell count
  • Swelling and redness along a vein, extremely sensitive to touch
  • Rash
  • Liver function changes detected by blood tests
  • Increased number of some white blood cells

Uncommon(may affect up to 1 in 100 people):

  • Local skin redness
  • Localized pain and formation of a firm lump at the injection site
  • Itching of the skin
  • Hives
  • Fever
  • Blood disorders that affect cells and are usually detected by a blood test (symptoms may be fatigue, pale skin, and prolonged bruising after injuries)
  • Kidney, liver, and blood changes detected by a blood test
  • Tremors and uncontrolled muscle contractions
  • Seizures
  • Mental changes (such as mood changes and impairment of mental faculties)
  • Seeing, hearing, or feeling something that is not there (hallucinations)
  • Confusion
  • Dizziness, drowsiness
  • Low blood pressure (hypotension)

Rare(may affect up to 1 in 1,000 people):

  • Allergic reactions such as skin rash, swelling of the face, lips, tongue, and/or throat (with difficulty breathing or swallowing) and/or low blood pressure (hypotension). If these side effects occur while receiving or after receiving imipenem/cilastatin, the administration of the medicine should be discontinued, and you should contact your doctor immediately.
  • Peeling of the skin (toxic epidermal necrolysis)
  • Severe skin reactions (Stevens-Johnson syndrome and erythema multiforme)
  • Severe skin rash with skin and hair loss (exfoliative dermatitis)
  • Fungal infection (candidiasis)
  • Discoloration of teeth and/or tongue
  • Inflammation of the colon with severe diarrhea
  • Changes in taste
  • The liver cannot perform its normal function
  • Inflammation of the liver
  • The kidney cannot perform its normal function
  • Changes in urine quantity, changes in urine color
  • Brain disease, tingling sensation (pins and needles), localized tremor
  • Hearing loss (hearing impairment)

Very rare(may affect up to 1 in 10,000 people):

  • Severe liver failure due to inflammation (fulminant hepatitis)
  • Inflammation of the stomach or intestine (gastroenteritis)
  • Inflammation of the intestine with bloody diarrhea (hemorrhagic colitis)
  • Redness and swelling of the tongue, excessive growth of the normal projections of the tongue, giving it a hairy appearance, heartburn, sore throat, increased saliva production
  • Stomach pain
  • Sensation of spinning (vertigo), headache
  • Ringing in the ears (tinnitus)
  • Pain in several joints, weakness
  • Irregular heartbeat, the heart beats strongly or rapidly
  • Chest discomfort, difficulty breathing, abnormally rapid and shallow breathing, pain in the upper back
  • Redness of the face (flushing), change in bluish discoloration of the face and lips, changes in skin texture, excessive sweating
  • Itching of the vulva in women
  • Changes in blood cell counts
  • Worsening of a rare disease associated with muscle weakness (increased severity of myasthenia gravis)

Frequency not known(cannot be estimated from the available data):

  • Abnormal movements
  • Agitation

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Surveillance System for Human Use: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Imipenem/Cilastatin Aurovitas

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the vials after “EXP”. The expiry date is the last day of the month stated.

Imipenem/Cilastatin Aurovitas dry vials: no special storage conditions are required.

After reconstitution:

The diluted solutions should be used immediately. The time interval between the start of reconstitution and the end of intravenous infusion should not exceed two hours.

Do not freeze the reconstituted solution.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

Composition of Imipenem/Cilastatin Aurovitas

  • The active substances are imipenem (as monohydrate) and cilastatin (as sodium salt).

Each vial of Imipenem/Cilastatin Aurovitas 500 mg/500 mg powder for solution for infusion contains 500 mg of imipenem (as 530 mg of imipenem monohydrate) and 500 mg of cilastatin (as 530 mg of cilastatin sodium salt).

  • The other component is sodium hydrogencarbonate.

Appearance of the product and pack size

Imipenem/Cilastatin 500 mg is presented in 20 ml capacity type III colorless glass vials, closed with a 20 mm diameter bromobutyl rubber stopper and a flip-off cap.

Pack sizes:

1 x vial of 500 mg

10 x vial of 500 mg

Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Eugia Pharma (Malta) Limited

Vault 14, Level 2, Valletta Waterfront

Floriana, FRN 1914

Malta

Manufacturer

ACS Dobfar S.p.A.

Nucleo Industriale S.Atto, S. Nicolò a Tordino

64100 Teramo

Italy

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Aurovitas Spain, S.A.U.

Avda. de Burgos, 16-D

28036 Madrid

Spain

Date of last revision of this leaflet: January 2018

Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

This information is intended only for healthcare professionals:

Each vial is for single use.

Preparation of the intravenous solution

The following table is provided to facilitate the reconstitution of Imipenem/Cilastatin Aurovitas for intravenous infusion.

Concentration

Recommended volume of diluent added (ml)

Approximate concentration of imipenem (mg/ml)

Imipenem/Cilastatin Aurovitas 500 mg

100

5

Reconstitution of Imipenem/Cilastatin Aurovitas 500 mg:

The contents of the vials should be dissolved and transferred to an appropriate infusion solution to achieve a volume of 100 ml.

A suggested procedure is to add approximately 10 ml of the infusion solution (see “Compatibility and stability”) to the vial. Shake well and transfer the resulting suspension to the infusion solution bottle.

CAUTION: THE SUSPENSION IS NOT FOR DIRECT INFUSION.

Repeat with an additional 10 ml of the infusion solution to ensure complete transfer of the vial contents to the infusion solution bottle. Make up to 100.0 with the same infusion solution. The resulting mixture should be shaken until a clear solution is obtained.

The concentration of the reconstituted solution, following the procedure described above, is approximately 5 mg/ml for both imipenem and cilastatin.

The reconstituted solution should be visually inspected for particles and/or color change before administration. Once reconstituted, the imipenem/cilastatin solution ranges from colorless to yellow. The color variation within this range does not affect the potency of the product.

Compatibility and stability

The reconstituted solutions should be used immediately. The time interval between the start of reconstitution and the end of intravenous infusion should not exceed two hours.

Imipenem/Cilastatin Aurovitas can be reconstituted in water for injection or in a 9 mg/ml (0.9%) sodium chloride infusion solution.

Do not freeze the reconstituted solution.

The disposal of unused medicine and all materials that have come into contact with it will be carried out in accordance with local regulations.

Online doctors for IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion

Discuss questions about IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (94)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (130)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (39)
Doctor

Jorge Correa Bellido

General medicine 7 years exp.

Dr. Jorge Correa Bellido is a Spanish physician who offers online consultations in Spanish and English. He graduated from the University of La Laguna and has a solid background in clinical practice and international research.

Throughout his career, he has participated in various medical and academic projects, including a research fellowship in Spain, where he contributed to evidence-based studies in the field of family medicine. This experience allowed him to broaden his global perspective on healthcare and comprehensive patient care.

Dr. Correa Bellido has worked with several healthcare providers in Spain, focusing particularly on patient-centered care and public health initiatives aimed at communities with limited access to healthcare services.

In addition, he actively participates in international medical conferences and workshops, which allows him to stay up to date with the latest medical advances and collaborate with healthcare professionals from different countries.

Dr. Correa Bellido provides comprehensive care for a wide variety of medical conditions, including:

  • respiratory infections
  • gastrointestinal disorders
  • cardiovascular problems
  • endocrine and metabolic diseases
  • musculoskeletal and dermatological conditions
  • as well as mental health conditions such as anxiety and depression.

He also treats infectious and allergic diseases, general health concerns, and provides guidance on prevention and healthy lifestyle habits.

His services include virtual consultations, diagnosis and management of acute and chronic diseases, prescription renewals, and personalized medical advice.

With a patient-centered approach and a strong commitment to continuous learning, Dr. Correa Bellido provides accessible and high-quality healthcare to patients both in Spain and around the world.

Camera Book a video appointment
€55
5.0 (49)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate

Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

Camera Book a video appointment
€50

Frequently Asked Questions

Is a prescription required for IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion?
IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion?
The active ingredient in IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion is imipenem and cilastatin. This information helps identify medicines with the same composition but different brand names.
Who manufactures IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion?
IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion is manufactured by Eugia Pharma (Malta) Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to IMIPENEM/CILASTATIN Aurovitas 500 mg/500 mg Powder for Solution for Infusion?
Other medicines with the same active substance (imipenem and cilastatin) include IMIPENEM/CILASTATIN HIKMA 500 mg/500 mg POWDER FOR SOLUTION FOR INFUSION, IMIPENEM/CILASTATIN KABI 500 mg/500 mg POWDER FOR SOLUTION FOR INFUSION, IMIPENEM/CILASTATIN STERISCIENCE 500 mg/500 mg POWDER FOR SOLUTION FOR INFUSION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media